BioSpace News Archive

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced results for the fiscal quarter ended June 30, 2023, and provided a business update.

Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 11,288,336 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “the Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced closing of the previously announced acquisition of AlterG, Inc. (“AlterG”).

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.

August 11, 2023—Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Plus Therapeutics, Inc. reported positive data from the ReSPECT-LM clinical study evaluating the Company’s lead radiotherapeutic, rhenium obisbemeda, for the treatment of leptomeningeal metastases at the Society for Neuro Oncology /American Society of Clinical Oncology Central Nervous System Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

HCW Biologics Inc. reported financial results and recent business highlights for its second quarter ended June 30, 2023.

Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.

Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical trial of Hexvix® for bladder cancer diagnosis met the primary endpoint.